Health Catalyst, Inc. (NASDAQ:HCAT) Insider Sells $10,803.84 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 1,324 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $8.16, for a total value of $10,803.84. Following the completion of the transaction, the insider now directly owns 114,275 shares in the company, valued at $932,484. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Linda Llewelyn also recently made the following trade(s):

• On Monday, September 16th, Linda Llewelyn sold 1,324 shares of Health Catalyst stock. The stock was sold at an average price of $8.43, for a total value of $11,161.32.
• On Thursday, August 15th, Linda Llewelyn sold 1,328 shares of Health Catalyst stock. The shares were sold at an average price of $6.57, for a total value of $8,724.96.

Health Catalyst Stock Up 0.1 %

Shares of Health Catalyst stock opened at $8.66 on Friday. Health Catalyst, Inc. has a 52 week low of $5.42 and a 52 week high of $11.41. The business has a 50 day moving average price of $7.71 and a 200-day moving average price of $6.94. The company has a market cap of $511.24 million, a PE ratio of -4.68 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The business had revenue of $75.90 million during the quarter, compared to analyst estimates of $74.96 million. During the same period in the prior year, the firm posted ($0.21) EPS. Health Catalyst’s quarterly revenue was up 3.7% compared to the same quarter last year. As a group, research analysts anticipate that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on HCAT shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Piper Sandler decreased their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. JPMorgan Chase & Co. increased their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Evercore ISI boosted their target price on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Finally, Stephens cut their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.58.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC grew its position in Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares in the last quarter. Quarry LP lifted its position in shares of Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares in the last quarter. nVerses Capital LLC purchased a new position in shares of Health Catalyst in the 3rd quarter worth approximately $59,000. Perfromance Wealth Partners LLC bought a new position in shares of Health Catalyst in the second quarter valued at approximately $64,000. Finally, Mackenzie Financial Corp purchased a new stake in shares of Health Catalyst during the second quarter valued at approximately $70,000. 85.00% of the stock is owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.